This pharma stock rose 21% after CLSA's rating change; Find out more
Updated : November 18, 2019 03:47 PM IST
Global brokerage CLSA upgraded Glenmark Pharma to 'buy' from 'sell' and raised its target price to Rs 410 per share from Rs 350 earlier.
The stock gained as much as 8.7 percent to Rs 327.60 per share on BSE.
Glenmark Pharma has advanced 16 percent in just 2 days post Q2 results.
Have you signed up for Primo, our daily newsletter?
It has all the stories and data on the market, business, economy and tech that you need to know.
THANK YOU! You made our day. See you every morning
YOUR EMAIL IS ON ITS WAY. Check your inbox for future updates.
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more